Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Avacta Group has entered into a license agreement with Biokit to incorporate Affimer reagents into a Biokit IVD product.
read more
Group announced it is shipping Affimer reagents for COVID-19 antigen testing to its diagnostic test development partners.
read more
Avacta has announce the first Affimer-based rapid test strips to detect SARS-COV-2 spike protein have been developed and evaluated by Avacta’s partners at Cytiva and show positive initial performance data.
read more
Avacta has begun work with the UK government’s CONDOR program to evaluate and clinically validate the high throughput COVID-19 bead-assisted mass spectrometry laboratory assay.
read more
Avacta Group announced collaborative work with the Centre for Virus Research at the University of Glasgow has shown that Affimer reagents which bind to the SARS-COV-2 virus spike protein prevent infection of human cells by a SARS-COV-2 model virus.
read more
Avacta has entered into a collaboration with Adeptrix to develop a high throughput COVID-19 antigen test using Adeptrix’s proprietary BAMS™ platform.
read more
Wednesday, September 02, 2020
Avacta Group has entered into an agreement with Abingdon Health for the manufacture of Avacta’s saliva-based rapid SARS-CoV-2 antigen test as part of its ongoing expansion of manufacturing capacity.
read more
Avacta Group announced the appointment of Neil Bell as Chief Development Officer of Avacta Life Sciences with immediate effect.
read more
Wednesday, August 12, 2020
Avacta Group has appointed BBI Solutions to manufacture the saliva-based rapid SARS-CoV-2 antigen test that is being developed with Cytiva.
read more
Tuesday, January 17, 2023
Avacta Group, a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics announces that AVA6000 continues to show a very favourable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation ...
read more
Tuesday, February 16, 2021
Avacta Group has received the first data for its SARS-CoV-2 rapid antigen test from ongoing clinical studies in Europe and the UK.
read more
Avacta Group plc, the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, announced that it has received notice of registration of its AffiDX® SARS-CoV-2 antigen lateral flow test in ...
read more
Thursday, January 07, 2021
Avacta Group has entered into a license agreement with POINT to provide access to Avacta’s pre|CISION technology for the development of tumor-activated radiopharmaceuticals.
read more
Friday, February 04, 2022
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces that the first-in-human Phase I trial (ALS-6000-101) of AVA6000 Pro-...
read more
Monday, February 01, 2021
Avacta has entered into a collaboration agreement with Bruker to evaluate the Affimer-based, bead assisted mass spectrometry SARS-CoV-2 assay, that the Group has developed with Adeptrix.
read more